| ¿µ¹® | Paget's disease | ÇÑ±Û | ÆÄÁ¦Æ®º´ |
|---|---|---|---|
| ¼³¸í | 1. »ÀÆÄÁ¦Æ®º´. º¯Çü¼º »À¿°. »ÀÈí¼ö ÈÄ »ÀÇü¼ºÀÌ ¹Ýº¹ÀûÀ¸·Î °úµµÇÏ°Ô ÀϾ´Â °ÍÀ¸·Î, »õ·Ó°Ô Çü¼ºµÈ »À´Â ¹«Áú¼ÇÏ°í ±¸Á¶ÀûÀ¸·Î °ß°íÇÏÁö ¸øÇÏ´Ù. »ÀÈí¼öÀÇ Áõ°¡°¡ ¹Ýº¹µÇ°í ÀÌ¾î¼ °úÀ׺¸¼ö¸¦ ²ÒÇÏ¿© ¾àÇÏ°í º¯ÇüµÈ »ÀÀÇ ºÎÇǰ¡ Áõ°¡µÇ´Â °ÍÀ» Ư¡À¸·Î ÇÏ´Â »Àº´ÀÌ´Ù. ±ÃµÕ»ÀÀÇ ¸¸°î, ÆíÆò»ÀÀÇ º¯ÇüÀ» ÀÏÀ¸Å°°í, µ¿Åë ¹× º´Àû °ñÀýÀ» ¼ö¹ÝÇÑ´Ù. 2. À¯¹æÆÄÁ¦Æ®º´. Á¥²ÉÆÇ ¹× Á¥²ÀÁöÀÇ ¿°Áõ¼º ¾Ï¼º Áúº´À¸·Î¼ º¸ÅëÀº Á¥»ù ¹× À¯¹æ ±íÀº °÷ÀÇ ¾ÏÀ» µ¿¹ÝÇÑ´Ù. º¸Åë Áß³âºÎÀο¡°Ô ¹ß»ýÇÑ´Ù. |
||
| ¿µ¹® | Parkinson disease | ÇÑ±Û | ÆÄŲ½¼º´ |
|---|---|---|---|
| ¼³¸í | ³ªÀÌµç »ç¶÷¿¡°Ô ¹ß»ýÇÏ´Â ½Å°æ°èÀÇ ÅðÇິÀÌ´Ù. ÁÖ·Î ¿îµ¿À» ´ã´çÇÏ´Â Áß°£³úºÎÀ§°¡ ħ¹üµÈ´Ù. ¿øÀÎÀº ¹ÙÀÌ·¯½º, ¾à¹°, ȤÀº µ¿¸Æ°æÈÁõ µîÀ¸·Î ¾Ë·ÁÁø °æ¿ìµµ ÀÖÀ¸³ª, ¿øÀÎÀ» ¾Ë ¼ö ¾ø´Â °æ¿ì°¡ ¸¹´Ù. Áõ»óÀº °¡¸é¾ó±¼, ¾²·¯Áú °Í °°Àº °ÉÀ½°ÉÀÌ, ¼Õ¶³¸², ±ÙÀ°ÀÇ °Á÷, ¾ÕÀ¸·Î ±â¿ï¾îÁø ÀÚ¼¼ µîÀÓ. Ä¡·á´Â Ưº°ÇÑ °ÍÀÌ ¾øÀ¸¸ç, ´ë°³ º¸Á¸Àû Ä¡·á(¿ÏÄ¡¸¦ ¸ñÀûÀ¸·Î ÇÏÁö ¾Ê°í ´ÜÁö ȯÀÚÀÇ »ýȰÀ» º¸Á¶ÇØÁÖ´Â Á¤µµÀÇ Ä¡·á)¸¦ ½ÃÇàÇÑ´Ù. ÃÖ±Ù, Á×Àº žÆÀÇ ³ú¸¦ À̽ÄÇÏ´Â ³ú À̽ļú¿¡ ÀÇÇÑ Ä¡·áÈ¿°ú°¡ ³ô´Ù´Â º¸°í°¡ ÀÖ´Ù. |
||
| ¿µ¹® | endemic disease | ÇÑ±Û | dzÅ亴 |
|---|---|---|---|
| ¼³¸í | Àΰ£»çȸ¿¡ Ç×»ó Á¸ÀçÇÏÁö¸¸ Ư¼öÇÑ ±âÈijª ÅäÁú·Î ÀÎÇÏ¿© ƯÁ¤Áö¿ª¿¡¸¸ Á¸ÀçÇÏ´Â »ç¸Á·üÀÌ ³·°í, ÀÓ»óÀûÀ¸·Îµµ µå¹°°Ô º¼ ¼ö ÀÖ´Â º´. ƯÈ÷ ±× ÅäÁöÀÇ Ç³Åä-±âÈÄ-»ý¹°-Åä¾ç µîÀÇ ÀÚ¿¬È¯°æ°ú ±× Áö¹æ ÁÖ¹ÎÀÇ Ç³¼Ó-½À°ü-ÀνÀ µîÀÌ º¹ÀâÇÏ°Ô ¾ôÇô¼ »ý±ä Ư¼öÇÑ º´À» °¡¸®Å²´Ù. ÀϹÝÀûÀ¸·Î ±× Áö¹æ ÁÖ¹ÎÀÇ »ç¸Á·üÀº ±×´ÙÁö ³ôÁö ¾ÊÁö¸¸ ±ÙÀýµÇ±â ¾î·Á¿î °ÍÀÌ Æ¯Â¡ÀÌ´Ù. Áö¹æº´À̶ó´Â ¸»Àº ¾î´À Áö¹æ¿¡ ÇÑÁ¤ÇÏ¿© º¼ ¼ö ÀÖ´Â º´À̶ó´Â Á¡¿¡¼´Â °°Áö¸¸, dzÅäȯ°æ°ú ¹ÐÁ¢ÇÑ °ü°è°¡ ÀÖ´Ù´Â µ¥¼ º¸¸é dzÅ亴À̶ó´Â ¿ë¾î°¡ ÀûÀýÇÏ´Ù. ±¹³»ÀûÀ¸·Î´Â ÂêÂê°¡¹«½Ãº´, ¾ß»ýÅä³¢º´, ·¾Å佺ÇǶóÁõ µîÀÌ ¾Ë·ÁÁ® ÀÖ°í, ¼¼°èÀûÀ¸·Î´Â ¸»¶ó¸®¾Æ, Ȳ¿, ÆäÆ®½º, ÀϺ»ÁÖÇ÷ÈíÃæÁõ µîÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. |
||
| ¿µ¹® | Hodgkin's disease | ÇÑ±Û | È£ÁöŲº´ |
|---|---|---|---|
| ¼³¸í | ¾Ç¼º¸²ÇÁÁ¾ÀÇ ÇÑ ÇüÅÂÀÌ´Ù. È£ÁöŲº´Àº ¹æ»ç¼± Ä¡·á¿¡ ´ë´ÜÈ÷ ¿¹¹ÎÇØ¼ ÃæºÐÇÑ ¾çÀÇ ¹æ»ç¼±À¸·Î ¿ÏÀüÇÑ ±ÙÄ¡Àû Ä¡·á°¡ °¡´ÉÇÏ´Ù. |
||
| CVD | cardiovascular disease; cerebrovascular disease; collagen vascular disease; color-vision-deviant |
|---|---|
| GBD | gallbladder disease; gender behavior disorder; glass blower's disease; granulomatous bowel disease |
| GD | gastroduodenal; Gaucher disease; general diagnostics; general dispensary; gestational day; Gianotti ... |
| ID | identification; iditol dehydrogenase; immunodeficiency; immunodiffusion; immunoglobulin deficiency; ... |
| ILD | interstitial lung disease; intraoperative localization device; ischemic leg disease; ischemic limb d... |
| time-varied gain control | In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation. Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain. (05 Mar 2000) |
|---|---|
| tonic control | Nerve impulses that maintain a normal tonus or level of activity in muscle or other effector organs. (05 Mar 2000) |
| topographical control | Those phenomena of cell behaviour in which the shape of the local substrate of the cell affects its behaviour. See: contact guidance. (18 Nov 1997) |
| transcriptional control | <molecular biology> Control of gene expression by controlling the number of RNA transcripts of a region of DNA. A major regulatory mechanism for differential control of protein synthesis in both pro and eukaryotic cells. (18 Nov 1997) |
| translational control | <molecular biology> The control of protein synthesis by regulation of the translation step, for example by selective usage of preformed mRNA or instability of the mRNA. (18 Nov 1997) |
| facility regulation and control | Formal voluntary or governmental procedures and standards required of hospitals and health or other facilities to improve operating efficiency, and for the protection of the consumer. (12 Dec 1998) |
| feedback control | The regulation of the activity of an enzyme by one of its products. (09 Oct 1997) |
| feedforward control | The process in which one of the products of a metabolic pathway induces an enzyme which participates in the metabolic pathway to act. (09 Oct 1997) |
| forms and records control | A management function in which standards and guidelines are developed for the developing, maintaining, and handling of forms and records. (12 Dec 1998) |
| locus control region | A regulatory region first identified in the human beta-globin locus but subsequently found in other loci. The region is believed to regulate transcription by opening and remodeling chromatin structure. It may also have enhancer activity. (12 Dec 1998) |
| locus of control | A theoretical construct designed to assess a person's perceived control over his/her own behaviour; classified as internal if the person feels in control of events, external if others are perceived to have that control. (05 Mar 2000) |
| aaa disease | Endemic anaemia of ancient Egypt, ascribed in the Papyrus Ebers to intestinal infestation with ancylostoma; now called ancylostomiasis. (05 Mar 2000) |
| ABO haemolytic disease of the newborn | Erythroblastosis foetalis due to maternal-foetal incompatibility with respect to an antigen of the ABO blood group; the foetus possesses A or B antigen which is lacking in the mother, and the mother produces immune antibody which causes haemolysis of foetal erythrocytes. (05 Mar 2000) |
| accumulation disease | A disease characterised by abnormal accumulation of a metabolic product in certain cells and tissues; examples include the mucopolysaccharidoses, lipoidoses. (05 Mar 2000) |
| Acosta's disease | A condition that results from prolonged exposure to high altitude. Symptoms include a continuous dry cough, shortness of breath, poor exercise tolerance, dizziness, headache, sleep difficulty, anorexia, confusion, fatigue and a rapid pulse. Treatment includes the immediate movement to a lower altitude. Prophylaxis has been accomplished successfully with the use of acetazolamide (Diamox). (27 Sep 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|